Robotic bronchoscopic ablation for small peripheral lung tumors
Bronchoscopic Lung Ablation of Small Thoracic Tumors: the Blastt Registry
This registry collects information on people with primary or metastatic peripheral lung tumors who have robotic-assisted bronchoscopic ablation to see how safe the procedure is and how well it controls tumors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT06840288 on ClinicalTrials.gov |
What this trial studies
This single-center observational registry at M.D. Anderson collects clinical, procedural, radiographic, and outcomes data from participants with known lung cancer or lung metastases who undergo robotic-assisted bronchoscopic ablation of peripheral tumors. It aggregates intra-operative, peri-operative, and long-term safety outcomes including bleeding, pneumothorax, and infection, and tracks oncologic outcomes such as local tumor progression by RECIST, LTPFS, PFS, DSS, and OS. The registry also analyzes serial imaging to characterize radiographic evolution of ablated lesions and evaluates tumor- and patient-level risk factors associated with safety and oncologic results. Procedures in which bronchoscopic ablation was planned but aborted for technical reasons are excluded from analysis.
Who should consider this trial
Good fit: Ideal candidates are people with peripheral lung tumors (primary lung cancer or metastases) who have undergone or are scheduled to undergo robotic-assisted bronchoscopic ablation with a completed ablation procedure.
Not a fit: Patients whose planned bronchoscopic ablations were aborted before completion, those with non-peripheral (central) tumors, or patients not treated with robotic bronchoscopic ablation are unlikely to benefit directly from this registry.
Why it matters
Potential benefit: If successful, the registry could help doctors better understand the safety and effectiveness of robotic bronchoscopic ablation and improve patient selection and follow-up care.
How similar studies have performed: Percutaneous thermal ablation has established evidence, while robotic-assisted bronchoscopic ablation is a newer approach with limited but growing early data supporting feasibility and safety.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients with peripheral lung tumors (primary or metastatic) that have been or will be ablated via robotic bronchoscopy. Exclusion Criteria: Patients with planned bronchoscopic ablations of peripheral lung tumors that were aborted for technical reasons (ablation was not completed).
Where this trial is running
Houston, Texas
- MD Anderson Cancer Center — Houston, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Roberto F Casal, MD — Prinicipal Investigator
- Study coordinator: Roberto F Casal, MD
- Email: rfcasal@mdanderson.org
- Phone: (713) 792-6238
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.